The application of combinatorial treatments with MEK and CDK4 inhibitors in multiple preclinical in vitro (dual fluorescence sensor system, 3D assays) and in vivo models (syngeneic and autochthonous mouse models) effectively prevented outgrowth of resistant tumor subpopulations and was substantially better than either monotherapy. Here, MAP2K7 is linked to neoplasm.